Eli Lilly and Company
LLY
$726.31
-$19.64-2.63%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 13.01% | -103.95% | 85.11% | -29.32% | 12.26% |
| Total Depreciation and Amortization | 3.39% | 13.25% | 4.99% | -16.85% | -15.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.40% | 298.40% | -1,263.90% | -164.33% | -62.06% |
| Change in Net Operating Assets | -284.88% | -14.48% | -1,102.00% | 578.43% | -73.70% |
| Cash from Operations | -118.76% | -1.23% | -46.60% | -31.41% | -22.90% |
| Capital Expenditure | -113.82% | -57.21% | -98.98% | -82.95% | -71.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -219.16% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -600.17% | -524.13% | 161.27% | 96.98% | -31.96% |
| Cash from Investing | -209.94% | -222.46% | 44.45% | 33.62% | -148.94% |
| Total Debt Issued | 1,988.37% | 125.80% | -100.00% | 692.18% | -- |
| Total Debt Repaid | -- | -- | 100.00% | -110.96% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 50.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.12% | -15.19% | -15.17% | -14.87% | -14.37% |
| Other Financing Activities | -130.66% | -30.77% | -105.26% | 0.50% | -2,183.33% |
| Cash from Financing | 410.56% | 145.28% | -735.41% | 114.32% | 25.23% |
| Foreign Exchange rate Adjustments | 200.86% | 247.22% | 113.26% | -26.19% | 41.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.54% | -5,603.64% | -620.10% | 208.80% | -1,916.50% |
